If you are in crisis or having thoughts of self-harm, please contact the 988 Suicide & Crisis Lifeline by calling or texting 988. You are not alone, and immediate help is available 24/7.
Could Your Depression Be Treatment-Resistant?
If medications haven't given you the relief you expected, you're not alone. Nearly a third of people with depression don't respond adequately to standard treatments. This assessment can help you understand where you stand and what options you may not have explored yet.
This assessment is for educational purposes only. It is not a diagnostic tool and does not replace professional medical evaluation. Your answers are not stored or shared. Option to answer more questions for a deeper analysis at the end.
Treatment-Resistant Depression Quiz: Find Out If Your Depression Is Treatment-Resistant
If your antidepressant medication isn't working, or if you've tried multiple medications without lasting relief, you may be dealing with treatment-resistant depression (TRD). About 30% of people with major depression find themselves in this position, and the frustration of failed treatment after failed treatment is something no one should have to navigate alone. The assessment above evaluates your medication history, symptom severity, and known risk factors to help you understand where you stand and what your next steps might be.
Understanding Treatment-Resistant Depression
Depression is one of the most common mental health conditions in the world, affecting roughly 280 million people globally. For most, a combination of antidepressant medication and therapy provides meaningful relief. But for a significant minority, the standard playbook simply doesn't work.
Treatment-resistant depression (TRD) is typically defined as major depressive disorder that hasn't responded adequately to at least two different antidepressant medications, each taken at the correct dose for at least 6-8 weeks. By this definition, about 30% of people with major depression meet the criteria for TRD.
That number may actually understate the problem. The STAR*D trial, the largest real-world depression treatment study ever conducted (4,041 patients across 41 sites), found that only 36.8% of patients achieved remission with their first antidepressant. After a second medication, the cumulative remission rate climbed to about 50-55%. But from there, the returns drop sharply. By the fourth medication attempt, fewer than 7% of patients respond. The data is clear: after two failed medications, the odds of the next pill being "the one" are low and falling.
Why Antidepressants Fail
If you're reading this, you've probably wondered whether the problem is you. It isn't. Antidepressants target specific neurotransmitter systems (most commonly serotonin), but depression is not a single-mechanism disease. Research increasingly shows that depression involves dysfunction in specific brain circuits, and those circuits vary from person to person. A medication that perfectly matches one person's neurochemistry may do nothing for another's.
There are also practical reasons that medications fail that have nothing to do with true treatment resistance. Researchers call this "pseudo-resistance," and it may account for up to 20% of cases labeled as TRD. Common causes include inadequate dosing or duration, medication non-adherence (which affects 30-60% of patients), unaddressed comorbidities like thyroid disorders or chronic pain, and misdiagnosis. About half of initial depression diagnoses turn out to be incomplete or incorrect, with bipolar disorder being the most frequently missed condition.
How This Assessment Works
The quiz above evaluates three dimensions that research has linked to treatment resistance: your treatment history (how many medications you've tried, whether they were adequate trials, and what other approaches you've explored), your current symptom severity (including functional impact and cognitive symptoms), and your risk factor profile (comorbidities, illness duration, family history, and childhood adversity).
Based on your responses, the assessment places you into one of four tiers, from early-stage depression that may still respond to optimized standard care, to significant treatment resistance that likely warrants a fundamentally different treatment approach. It also flags potential pseudo-resistance factors that may be worth discussing with your provider.
This is not a clinical diagnosis. It's a starting point for a more informed conversation with your healthcare team.
Treatment Options When Antidepressants Don't Work
If you've reached the point where medications aren't providing adequate relief, the question becomes: what else is there? The answer, fortunately, is more than most people realize. Here's how the major treatment options compare based on published clinical trial data.
| Treatment | Remission Rate | Timeline | Key Consideration |
|---|---|---|---|
| 3rd+ Medication Trial | 7-14% | 6-8 weeks | Diminishing returns per STAR*D data |
| Medication Augmentation | 15-30% | 4-8 weeks | Added side effect burden |
| Standard TMS (rTMS) | ~30% | 4-6 weeks (30-36 sessions) | FDA-approved; generic targeting |
| Deep TMS | 58-65% | 4 weeks (20 sessions) | Broader stimulation area |
| ECT | 50-60% | 3-4 weeks | Requires anesthesia; memory side effects |
| Ketamine/Spravato | ~30% | Hours to days | Rapid but temporary; requires ongoing sessions |
| fMRI-Guided Accelerated TMS | 50-79% | 5 days | Personalized brain imaging; non-invasive |
Remission rates reflect published clinical trial data. Individual results vary based on patient characteristics and study design.
Why Personalized Brain Imaging Matters
Standard TMS uses a one-size-fits-all approach to locate the treatment target on the brain. The most common method (the "5-cm rule" or F3 formula) estimates the target location based on skull measurements or generic coordinates. But a landmark 2012 study analyzing 98 TMS treatment sites found that the clinical effectiveness of different stimulation points was strongly predicted by their functional connectivity to a specific brain region called the subgenual anterior cingulate cortex (sgACC). Sites with stronger negative connectivity to the sgACC produced better outcomes, explaining 76% of the variance in clinical response.
The problem? The optimal target varies by several millimeters from person to person. And a 3,001-patient imaging study (the DIRECT Consortium) found that the ideal TMS target actually differs between depressed and healthy brains, meaning targets derived from healthy brain templates may be systematically off for the patients who need them most.
fMRI-guided TMS solves this by scanning each patient's brain before treatment to identify their specific optimal target based on their unique neural connectivity patterns. When this personalized targeting is combined with an accelerated protocol (50 sessions over 5 days) and concurrent cognitive behavioral therapy, the results have been striking. The original Stanford SAINT trial achieved 90.5% remission in treatment-resistant patients. Controlled trials confirmed 50-79% remission rates, and a 2026 independent replication validated these findings with 50% remission at one month versus 20.8% for sham.
The Role of CBT in TMS Treatment
One finding that often gets overlooked is how much better TMS works when paired with psychotherapy. A 2023 study found that combining TMS with cognitive behavioral therapy was 7 times more effective at achieving remission than CBT combined with antidepressant medication alone. A separate naturalistic study of 196 patients (97% of whom had treatment-resistant depression) found that simultaneous TMS plus psychotherapy produced a 66% response rate and 56% remission rate, with 60% maintaining remission at 6 months.
The likely explanation is synergy: TMS enhances neuroplasticity in the prefrontal cortex, essentially making the brain more receptive to learning new thought patterns at the same time CBT is actively teaching those patterns.
Frequently Asked Questions About Treatment-Resistant Depression
Treatment-resistant depression (TRD) is a form of major depressive disorder that does not improve adequately after trying at least two different antidepressant medications at the right dose for the right duration (typically 6-8 weeks each). About 30% of people diagnosed with major depression meet this criteria.
TRD is not a character flaw or a sign that someone isn't trying hard enough. It reflects differences in brain circuitry that simply don't respond to the mechanisms these medications target. Research increasingly points to the need for personalized treatment approaches, including brain imaging and neuromodulation, for patients who have exhausted standard medication options.
The clinical hallmark is inadequate response to two or more adequate antidepressant trials. But there are nuances worth understanding. Key signs include: you've tried multiple medications with little or no lasting improvement, symptoms improved temporarily but always return, you've been dealing with depression for more than two years, side effects forced you to stop medications before they could work, or you've tried therapy, lifestyle changes, and medication without lasting relief.
The assessment at the top of this page is designed to help you evaluate these factors systematically and determine whether your pattern matches what researchers see in treatment-resistant populations.
The FDA and European Medicines Agency both define TRD as failure to respond to at least two adequate antidepressant trials. "Adequate" means the correct dose taken consistently for at least 6-8 weeks. If you stopped a medication early due to side effects, or if the dose was never titrated to its therapeutic range, that may not count as a true failed trial.
Data from the STAR*D trial shows that after two failed medications, each subsequent medication attempt has sharply diminishing returns. By the fourth attempt, fewer than 7% of patients respond to any individual new medication. Many clinicians now view TRD on a spectrum rather than as a binary label, with tools like the Maudsley Staging Method used to grade the severity of treatment resistance.
Pseudo-resistance occurs when depression appears treatment-resistant but actually has a correctable underlying cause. Researchers estimate that up to 20% of cases labeled as TRD may fall into this category.
Common causes of pseudo-resistance include medication non-adherence (which affects 30-60% of patients), inadequate dose or duration of treatment, misdiagnosis (about 50% of depression cases are initially misdiagnosed, especially bipolar disorder presenting as depression), unaddressed comorbidities like thyroid disorders or substance use, and pharmacogenomic differences that cause medications to be metabolized too quickly or too slowly. A thorough diagnostic re-evaluation is an important step before pursuing advanced treatments.
Options beyond standard antidepressants include medication augmentation (adding lithium, thyroid hormone, or atypical antipsychotics), standard repetitive TMS with remission rates around 30%, deep TMS with remission rates of 58-65%, electroconvulsive therapy with remission rates of 50-60% but potential memory side effects, ketamine or esketamine (Spravato) with rapid but often temporary relief, and accelerated fMRI-guided TMS protocols which have achieved 50-79% remission in clinical trials over just 5 days.
Combining any form of TMS with cognitive behavioral therapy has shown particularly strong results. One study found that the combination was 7 times more effective at achieving remission than CBT plus medication alone.
fMRI-guided TMS uses functional magnetic resonance imaging to map an individual's unique brain connectivity patterns before beginning transcranial magnetic stimulation treatment. Standard TMS targets a generic location on the prefrontal cortex using a one-size-fits-all approach, but research shows the optimal stimulation target varies by several millimeters from person to person.
The fMRI scan identifies the specific spot on each patient's prefrontal cortex that has the strongest functional connection to the subgenual anterior cingulate cortex, a brain region consistently implicated in depression. A 3,001-patient imaging consortium found that this ideal target actually differs between depressed and healthy brains, meaning generic targets may be systematically off for depression patients. Personalized targeting based on fMRI connectivity has been shown to predict treatment outcomes with 84-88% accuracy.
The SAINT protocol (Stanford Accelerated Intelligent Neuromodulation Therapy), also called SNT, is an accelerated, fMRI-guided TMS protocol developed at Stanford University. It delivers 10 treatment sessions per day over 5 consecutive days (50 total sessions), using intermittent theta-burst stimulation with 50-minute intervals between sessions. The protocol targets a personalized brain location identified through functional MRI imaging.
In the original open-label study, 90.5% of treatment-resistant patients achieved remission. A randomized controlled trial showed 79% of patients reached remission at some point during the follow-up period. A 2026 independent replication study further validated the results, with 50% remission at one month versus 20.8% for sham treatment, confirming the protocol's reproducibility.
While "cure" is a strong word in psychiatry, treatment-resistant depression can absolutely go into sustained remission with the right approach. Accelerated fMRI-guided TMS has produced remission rates of 50-79% in patients who had already failed multiple medications. A 2025 durability study found that 47% of patients maintained remission at 3 months without any maintenance treatment.
Among those who eventually relapsed, 91% responded to retreatment, often requiring only 1-2 days rather than the full 5-day protocol. The key insight is that TRD often requires a fundamentally different treatment approach rather than continued medication trials with diminishing returns.
Approximately 30% of people diagnosed with major depressive disorder develop treatment-resistant depression. A 2025 analysis of the All of Us Research Program found a TRD prevalence of 19% among medicated depression patients specifically. The STAR*D trial found that after two adequate medication trials, roughly 45% of patients had still not achieved remission.
While fewer than 20% of depression cases progress to severe treatment resistance, these patients account for a disproportionate share of the burden: 31-54% of total depression-related healthcare costs. TRD patients cost an average of $6,709 more per year than non-TRD depression patients and are twice as likely to be hospitalized.
Research has identified several factors associated with higher risk, including earlier age of depression onset (especially before age 18), longer duration of the current depressive episode, greater symptom severity, comorbid anxiety disorders (the most consistent predictor), chronic pain conditions, history of childhood trauma or adverse childhood experiences, substance use disorders, multiple lifetime episodes, family history of depression, obesity, and personality disorders.
That said, treatment pathways are highly variable. Both responsive and non-responsive patients show considerable diversity in their clinical presentations, so no single risk factor profile guarantees treatment resistance. The full assessment at the top of this page evaluates multiple risk factors together to give you a more complete picture.
No. This assessment is designed for educational purposes only. It evaluates self-reported information about your medication history, symptom severity, and known risk factors to help you understand your situation and have a more informed conversation with your healthcare provider. Only a qualified medical professional can diagnose treatment-resistant depression after a thorough clinical evaluation, which typically includes a detailed treatment history review, diagnostic reassessment, and consideration of comorbid conditions.
Related Resources from Cognitive FX
- Why Aren't My Antidepressant Medications Working? A detailed guide to why antidepressants fail and what to do next, including signs to watch for and questions to ask your doctor.
- What to Do When SSRIs Don't Work Understanding SSRI failure, antidepressant tachyphylaxis, and evidence-based alternatives including TMS therapy.
- fMRI-Guided TMS for Treatment-Resistant Depression Learn how Cognitive FX uses functional brain imaging and accelerated TMS protocols to treat depression that hasn't responded to medication.
- Transparent Treatment Pricing Our treatment pricing is published openly. No hidden numbers, no surprise billing.
- Cognitive FX Blog Research-backed articles on brain injury, depression treatment, TMS therapy, and neurological recovery.
Still Have Questions?
Our clinical team can help you understand your results and explore whether fMRI-guided TMS might be right for your situation. Consultations are free and come with no obligation, and treatment pricing is published openly on our site.
See If You're a Candidate →Or call (385) 375-8590